Where does LPAA stock trade?

Launch One Acquisition Corp. (LPAA) is listed on NASDAQ.

When did Launch One Acquisition Corp. go public?

Launch One Acquisition Corp. (LPAA) completed its IPO in 2024.

How can I track LPAA on Quantisnow?

Quantisnow aggregates Launch One Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LPAA to receive live email and push alerts on every new disclosure.

LPAA

NASDAQ

Launch One Acquisition Corp.

IPO2024

News25/Ratings0

News · 26 weeks150%

2026-03-012026-08-23

Mix1090d

SEC Filings7(70%)
Other2(20%)
Insider1(10%)

Latest news

25 items

12dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
13dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
43dSEC
Launch One Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
49dSEC
Launch One Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
61dSEC
SEC Form DEFA14A filed by Launch One Acquisition Corp.
DEFA14A - Launch One Acquisition Corp. (0002015502) (Filer)
61dSEC
SEC Form 8-K filed by Launch One Acquisition Corp.
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
76dSEC
SEC Form DEF 14A filed by Launch One Acquisition Corp.
DEF 14A - Launch One Acquisition Corp. (0002015502) (Filer)
84dSEC
SEC Form PRER14A filed by Launch One Acquisition Corp.
PRER14A - Launch One Acquisition Corp. (0002015502) (Filer)
84dINSIDER
SEC Form 3 filed by new insider Rogers Daniel C
3 - Launch One Acquisition Corp. (0002015502) (Issuer)
84dSEC
SEC Form 8-K filed by Launch One Acquisition Corp.
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
99dSEC
SEC Form PRE 14A filed by Launch One Acquisition Corp.
PRE 14A - Launch One Acquisition Corp. (0002015502) (Filer)
103dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
151dSEC
SEC Form 10-K filed by Launch One Acquisition Corp.
10-K - Launch One Acquisition Corp. (0002015502) (Filer)
152dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)
152dSEC
Launch One Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
193dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
193dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
193dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
194dSEC
SEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.
SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
195dSEC
SEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.
SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
224dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)
224dPR
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding
278dPR
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company's mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology's (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-
285dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
314dPR
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track Designation in MDS, as well as both Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome. "We continue to receive

LPAA FAQ

3 questions

Where does LPAA stock trade?
Launch One Acquisition Corp. (LPAA) is listed on NASDAQ.
When did Launch One Acquisition Corp. go public?
Launch One Acquisition Corp. (LPAA) completed its IPO in 2024.
How can I track LPAA on Quantisnow?
Quantisnow aggregates Launch One Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LPAA to receive live email and push alerts on every new disclosure.